// App-Quantinova.ai

8001 : Lenalidomide, doxorubicin hydrochloride, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.

Researchers

Presenter

  • Stefan Knop

Principal Investigators

  • Monika Martha Engelhardt

  • Johanne Wangemann

  • Lars Olof Muegge

  • Florian Bassermann

  • Kerstin Schaefer-Eckart

  • Igor W. Blau

  • Denise Wolleschak

  • Albrecht Reichle

  • Ivana von Metzler

  • Bernd Metzner

  • Christoph Rollig

  • Bernd Hertenstein

  • Michael Pfreundschuh

  • Tim H. Brummendorf

  • Martin Gramatzki

  • Matthias Ritgen

  • Swantje Held

  • Hermann Einsele

Medical Centers

  • Medizinische Klinik und Poliklinik II, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany

  • Universitatsklinikum Ulm, Klinik fur Innere Medizin I, Ulm, Ulm, Germany

  • Radiation Oncology Department, University of Freiburg, Freiburg, Germany

  • Schleswig-Holstein University Hospital, Kiel, Germany

  • Essen University Hospital, Essen, Germany

  • Department of Pediatrics, Technische Universitat Munchen, Munich, Germany

  • Nuremberg Hospital, Nuremberg, Germany

  • Department of Internal Medicine III, Charite Campus Benjamin Franklin, Berlin, Germany

  • Magdeburg University Hospital, Magdeburg, Germany

  • Regensburg University Hospital, Regensburg, Germany

  • Frankfurt University, Frankfurt, Germany

  • Klinikum Oldenburg AoR, Medical Campus University Oldenburg, Oldenburg, Germany

  • Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

  • Department of Hematology and Oncology, Klinikum Bremen Mitte, Bremen, Germany

  • University Saarland Medical School, Homburg Saar, Germany

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Kiel, Germany

  • Medical Department II, University Schleswig Holstein in the City Hospital Kiel, Kiel, Germany

  • ClinAssess GmbH, Leverkusen, Germany

  • Department of Medicine II, University of Wuerzburg, Wuerzburg, Germany

Locations

  • Germany

Companies

  • ClinAssess GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Doxorubicin Hydrochloride

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Doxorubicin

  • Bortezomib

Outcome

  • N/A

Study Design

  • Non Inferiority

Phase

  • NA

Study Id's

  • NCT01685814

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved